Published in
Taylor and Francis Group, OncoImmunology, 9(3), p. e955697
DOI: 10.4161/21624011.2014.955697
Links
- ORCID
- Taylor and Francis Group | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
The therapeutic efficacy of the oncolytic virus Delta24-RGD in a murine glioma model depends primarily on antitumor immunity
Journal article published in 2014 by
Anne Kleijn,
Jenneke Kloezeman,
Elike Treffers-Westerlaken,
Giulia Fulci,
Sieger Leenstra,
Clemens Dirven,
Reno Debets,
Martine Lamfers 
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Oncolytic viruses selectively lyse tumor cells, making these agents a promising treatment modality for glioma. Accumulating data suggest that the immune system plays an important role in the anti-glioma activity of oncolytic viruses. In an immune competent glioma model, the therapeutic effect of the oncolytic adenovirus Delta24-RGD was found to depend primarily on antitumor immune responses.